2. Metabolic Enzyme/Protease Neuronal Signaling GPCR/G Protein Apoptosis
  3. Endogenous Metabolite mGluR Apoptosis
  4. Xanthurenic acid

Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus.

For research use only. We do not sell to patients.

Xanthurenic acid Chemical Structure

Xanthurenic acid Chemical Structure

CAS No. : 59-00-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
100 mg USD 50 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Xanthurenic acid:

Xanthurenic acid Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Xanthurenic acid

View All mGluR Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus.

IC50 & Target[1]

Human Endogenous Metabolite

 

mGluR2

 

mGluR3

 

In Vivo

Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. The inhibition of Xanthurenic acid (XA) on sensory can be found when applied iontophoretically and i.v., is similar to that of other Group II mGlu receptor agonists in reducing inhibition evoked in the VB from the thalamic reticular nucleus upon physiological sensory stimulation. Furthermore, it is postulated that Xanthurenic acid may be the first potential endogenous allosteric agonist for the mGlu receptors. As the Group II receptors and kynurenine metabolism pathway have both been heavily implicated in the pathophysiology of schizophrenia, Xanthurenic acid could play a pivotal role in antipsychotic research as this potential endocoid represents both a convergence within these two biological parameters and a novel class of Group II mGlu receptor ligand[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

205.17

Formula

C10H7NO4
CAS No.
Appearance

Solid

Color

Light yellow to brown

SMILES

O=C(C1=NC2=C(O)C=CC=C2C(O)=C1)O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 8.93 mg/mL (43.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8740 mL 24.3700 mL 48.7401 mL
5 mM 0.9748 mL 4.8740 mL 9.7480 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 20 mg/mL (97.48 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.94%

COA (251 KB) HNMR (253 KB) LCMS (254 KB)

Handling Instructions (2659 KB)
References
Animal Administration
[1]

Rats[1] Male Wistar rats (265-495 g, n=27) are used throughout the study. Throughout the experiments, electrocardiogram and electroencephalogram (EEG) are monitored. Iontophoretic drug applications are performed using the outer barrels, with one of the outer barrels filled with 1 M NaCl for current balancing on each occasion. The remaining outer barrels contain one of the following substances as required: NMDA (50 mM,pH8.0 in 150 mM NaCl), LY354740 (5 mM, pH8.0 in 75 mM NaCl), Xanthurenic Acid (5 mM, pH8.0 in 75 mM NaCl), LY341495 (5 mM, pH8.5 in 75mM NaCl), as Nat salts, ejected as anions, and LY487379 (1 mM, pH6.0, in 1% dimethyl sulfoxide, 75mM NaCl), ejected as cations. All compounds are prevented from diffusing out of the pipette by using a retaining current (15-25 nA) of opposite polarity to that of the ejection current[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.8740 mL 24.3700 mL 48.7401 mL 121.8502 mL
5 mM 0.9748 mL 4.8740 mL 9.7480 mL 24.3700 mL
10 mM 0.4874 mL 2.4370 mL 4.8740 mL 12.1850 mL
15 mM 0.3249 mL 1.6247 mL 3.2493 mL 8.1233 mL
20 mM 0.2437 mL 1.2185 mL 2.4370 mL 6.0925 mL
25 mM 0.1950 mL 0.9748 mL 1.9496 mL 4.8740 mL
30 mM 0.1625 mL 0.8123 mL 1.6247 mL 4.0617 mL
40 mM 0.1219 mL 0.6093 mL 1.2185 mL 3.0463 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Xanthurenic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Xanthurenic acid59-00-7Endogenous MetabolitemGluRApoptosisMetabotropic glutamate receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Xanthurenic acid
Cat. No.:
HY-W014666
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.